CAR-T Cell Therapy: Revolutionizing Cancer Treatment
Abstract
CAR-T cell therapy has emerged as a groundbreaking approach in cancer treatment, offering new hope for patients with refractory and relapsed malignancies. This literature review provides a comprehensive overview of the development, applications, and future directions of CAR-T cell therapy. We explore the principles behind CAR-T cell engineering, highlight the clinical successes and challenges in treating hematologic malignancies, and discuss the potential and hurdles in targeting solid tumors. The review also examines the safety profiles, including adverse effects management, and delves into the mechanisms of resistance and relapse. Furthermore, we address regulatory and ethical considerations, patient perspectives, and the innovative advancements shaping the future of CAR-T cell therapy. By synthesizing current research and clinical data, this review underscores the transformative impact of CAR-T cell therapy in oncology and its promising trajectory in the fight against cancer.
Keywords: CAR-T cell therapy, cancer treatment, hematologic malignancies, solid tumors, next-generation CAR-T.
Full Text:
PDFReferences
Aghajanian, H., Rurik, J.G., and Epstein, J.A., 2022, CAR-based therapies: opportunities for immuno-medicine beyond cancer, Nature metabolism, 4(2), 163–169. CrossRef
Brudno, J.N., Kochenderfer, J.N., 2018, Chimeric antigen receptor T-cell therapies for lymphoma, Nat Rev Clin Oncol., 17(5), 289-305. CrossRef
Chen, Q., Lu, L., and Ma, W., 2022, Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors, Cancers (Basel), 14(23), 5983. CrossRef
Chou, C.K., and Turtle, C.J., 2020, Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy, Expert opinion on biological therapy, 20(6), 653–664. CrossRef
FDA Approves First CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. Leukemia and Lymphoma Society. March 19, 2024. Link
FDA Approves Liso-cel. CLL Society. March 15, 2024. Link
Fischer, J.W., and Bhattarai, N., 2021, CAR-T cell therapy: Mechanism, management, and mitigation of inflammatory toxicities, Front Immunol., 12, 693016. CrossRef
Gauthier, J., Gazeau, N., Hirayama, A.V., Hill, J.A.,Wu, V., Cearley, A., et al., 2022, Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL, Blood, 139(26), 3722-3731. CrossRef
Gogishvili, T., Danhof, S., Prommersberger, S., Rydzek, J., Schreder, M., Brede, C., et al., 2017, SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes, Blood, 130(26), 2838-2847. CrossRef
Guzman, G., Reed, M.R., Bielamowicz, K., Koss, B., and Rodriguez, A., 2023, CAR-T Therapies in Solid Tumors: Opportunities and Challenges, Current oncology reports, 25(5), 479–489. CrossRef
Imbach, K.J., Patel, A., and Levine, A.D., 2018, Ethical Considerations in the Translation of CAR-T Cell Therapies, Cell and Gene Therapy Insights, 4(4), 295–307. CrossRef
Jiang, D., Huang, H., Qin, H., Tang, K., Shi, X., Zhu, T., et al., 2023, Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour- specific responses in murine xenograft models of multiple myeloma, Nat Commun., 14, 3642. CrossRef
Khoshandam, M., Soltaninejad, H., Hamidieh, A.A., and Hosseinkhani, S., 2023, CRISPR, CAR-T, and NK: Current applications and future perspectives, Genes & diseases, 11(4), 101121. CrossRef
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., 1987, Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived c regions, Biochem Biophys Res Commun., 149(3), 960-968. CrossRef
Lantidra. Outlook on Cell and Gene Therapy: 2024 and Beyond. Labcompare, 2024.
Lee, H., Ahn, S., Maity, R., Lebly, N., Ziccheddu, B., Truger, M., et al., 2023, Mechanisms of antigen escape from BCMA-or GPRC5Dtargeted immunotherapies in multiple myeloma, Nat Med., 29, 2295-2306. CrossRef
Lin, Y.J., Mashouf, L.A., and Lim, M., 2022, CAR T cell therapy in primary brain tumors: Current investigations and the future, Frontiers in Immunology, 13, 817296. CrossRef
Maakaron, J.E., Hu, M., and El Jurdi, N., 2022, Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations, BMJ, 378, e068956. CrossRef
Marks P., 2024, Regulatory pathways for CAR-T cell therapies: navigating challenges, FDA.
Marofi, F., Motavalli, R., Safonov, V.A., Thangavelu, L., Yumashev, A.V., Alexander, M., et al., 2021, CAR T cells in solid tumors: challenges and opportunities, Stem Cell Research & Therapy, 12, 81. CrossRef
Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., et al., 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med., 387(5), 439-448. CrossRef
National Cancer Institute, 2022, Engineering CAR T-cell therapy to overcome limitations. Retrieved from https://www.cancer.gov/news-events/cancer-currents-blog/2022/car-t-cell-therapy-limitations.
Neelapu, S.S., Locke, F.L., Bartlett, N.L., Lekakis, L.J., Miklos, D.B., Jacobson, C.A., et al., 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med., 377, 2531-2544.
Nerreter, T., Letschert, S., Gotz, R., Doose, S., Danhof, S., Einsele, H., et al., 2019, Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CAR-T cells, Nat Commun., 10(1), 3137.
Newick, K., O’Brien, S., Moon, E., and Albelda, S.M., 2017, CAR T-cell therapy for solid tumors, Annu Rev Med., 68, 139-152.
Rafiq, S., Hackett, C.S., and Brentjens, R.J., 2020, Engineering strategies to overcome the current roadblocks in CAR T cell therapy, Nat Rev Clin Oncol., 17(3), 147-167.
Rath, J.A., and Arber, C., 2020, Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy, Cells, 9(6), 1485.
Samur, M.K., Fulciniti, M., Samur, A.A., Bazarbachi, A.H., Tai, Y-T., Prabhala, R., et al., 2021, Biallelic loss of BCMA as a resistance mechanism to CART cell therapy in a patient with multiple myeloma, Nat Commun., 12, 868.
Sana Biotechnology, Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting, 2022.
Schmidt, P., Raftery, M.J., and Pecher, G., 2020, Engineering NK cells for CAR therapy–recent advances in gene transfer methodology, Front Immunol., 11, 611163.
Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., et al., 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med., 380, 45-56.
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H.J., Schlober, H.A., Schlaak, M., et al., 2018, Cytokine release syndrome, J Immunother Cancer, 6(1), 56.
Sidana, S., Dueck, A.C., Thanarajasingam, G., Griffin, J.M., Thompson, C., Durani, U., et al., 2022, Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant, Transplantation and cellular therapy, 28(8), 473–482.
Sorkhabi, A.D., Khosroshahi, L.M., Sarkesh, A., Mardi, A., Aghebati-Maleki, A., Aghebati-Maleki, L., and Baradaran, B., 2023, The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies, Frontiers in immunology, 14, 1113882.
Xin, T., Cheng, L., Zhou, C., Zhao, Y., Hu, Z., and Wu, X., 2022, In-vivo induced CAR-T cells for the potential breakthrough to overcome the barriers of current CAR-T cell therapy, Frontiers in Oncology, 12, 809754.
DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev15iss1pp76-86
Copyright (c) 2024 Indonesian Journal of Cancer Chemoprevention
Indexed by:
Indonesian Society for Cancer Chemoprevention
